Investment Rating - The report maintains a "Strong Buy" rating for the company [2][5]. Core Insights - The company reported a robust performance in the first half of 2025, achieving a revenue of 8.512 billion yuan, representing a year-over-year increase of 17.23%, and a net profit of 740 million yuan, up 21.82% year-over-year [3]. - The core business segments showed steady growth, with the functional products segment revenue increasing by 20% to 6.47 billion yuan, driven by the growth in methionine sales and an increase in market penetration of liquid methionine [3]. - The special products segment also saw a revenue increase of 9% to 2.04 billion yuan, attributed to strong sales growth in ruminant products outside of China and a rebound in aquatic product sales [3]. - The company is enhancing its methionine production capacity, with ongoing projects in Europe and China, including a new solid methionine plant in Quanzhou expected to be operational by 2027 [4]. Financial Performance Summary - The company’s EBITDA margin improved to 22% in the first half of 2025, benefiting from cost control and operational efficiency initiatives [3]. - The financial forecast for 2025-2027 estimates net profits of 1.637 billion, 1.852 billion, and 2.025 billion yuan, with corresponding EPS of 0.61, 0.69, and 0.75 yuan [5]. - The projected revenue for 2025 is 17.939 billion yuan, with a growth rate of 15.48% [6]. Company Overview - The company is recognized as the second-largest methionine producer globally, capable of producing both solid and liquid methionine, and is a leader in the animal nutrition and health industry [7].